Description

VICTOFOL INJ 10ML

Indications

VICTOFOL INJ 10ML is primarily indicated for the management of various conditions related to folate deficiency. It is commonly used in patients with megaloblastic anemia due to folate deficiency, which can arise from inadequate dietary intake, malabsorption syndromes, or increased physiological demands such as during pregnancy. Additionally, VICTOFOL may be utilized in certain cases of hyperhomocysteinemia, which is associated with cardiovascular diseases. The injection form allows for rapid absorption and is particularly beneficial in patients who may have difficulty with oral supplementation.

Mechanism of Action

The active ingredient in VICTOFOL is folic acid, a water-soluble B vitamin that plays a crucial role in DNA synthesis, repair, and methylation. Folic acid is converted into its active form, tetrahydrofolate, in the body. Tetrahydrofolate is essential for the synthesis of purines and pyrimidines, which are the building blocks of DNA and RNA. By facilitating the conversion of homocysteine to methionine, folate helps to regulate homocysteine levels, thereby potentially reducing the risk of cardiovascular diseases. The injection form of VICTOFOL ensures that the folate is readily available for cellular uptake and utilization, especially in patients with absorption issues.

Pharmacological Properties

VICTOFOL INJ 10ML contains folic acid, which is known for its high bioavailability when administered parenterally. Following injection, folic acid is quickly absorbed into the bloodstream and distributed throughout the body. The pharmacokinetics of folic acid indicate that it has a half-life of approximately 6 hours, with a peak plasma concentration occurring within 30 to 60 minutes post-administration. Folic acid is primarily excreted via the kidneys, and its pharmacological effects are most pronounced in tissues with high turnover rates, such as bone marrow and the gastrointestinal tract.

Contraindications

VICTOFOL INJ 10ML is contraindicated in individuals who have a known hypersensitivity to folic acid or any of the excipients in the formulation. It should also be avoided in patients with untreated pernicious anemia or other forms of anemia that are not responsive to folate supplementation, as these conditions may require different therapeutic approaches. Additionally, caution is advised in patients with a history of seizures, as high doses of folic acid may exacerbate seizure activity in susceptible individuals.

Side Effects

While VICTOFOL INJ 10ML is generally well-tolerated, some patients may experience side effects. Commonly reported adverse reactions include mild gastrointestinal disturbances such as nausea, vomiting, and abdominal discomfort. Allergic reactions, although rare, can occur and may present as rash, itching, or swelling. In some cases, patients may experience transient changes in mood or sleep disturbances. It is essential for healthcare providers to monitor patients for any unusual symptoms following administration of the injection.

Dosage and Administration

The recommended dosage of VICTOFOL INJ 10ML is typically determined by the severity of the folate deficiency and the underlying condition being treated. For adults, the usual dose for megaloblastic anemia is 1 to 5 mg administered intramuscularly or intravenously once daily until hematological parameters improve. For maintenance therapy, a lower dose may be prescribed. In pregnant women, the dosage may be adjusted based on dietary intake and individual needs. It is crucial to follow the healthcare provider’s instructions regarding the administration route and frequency to ensure optimal therapeutic outcomes.

Interactions

VICTOFOL INJ 10ML may interact with certain medications, potentially affecting its efficacy or increasing the risk of side effects. Anticonvulsants, such as phenytoin and phenobarbital, may reduce folate levels in the body, necessitating increased doses of folic acid. Additionally, methotrexate, a medication used in cancer therapy and autoimmune diseases, can interfere with folate metabolism, leading to increased toxicity. It is essential for healthcare providers to review a patient’s medication list thoroughly to identify potential drug interactions before initiating treatment with VICTOFOL.

Precautions

Before administering VICTOFOL INJ 10ML, healthcare providers should conduct a thorough assessment of the patient’s medical history and current health status. Special precautions should be taken in patients with a history of renal impairment, as folic acid is primarily excreted by the kidneys. Regular monitoring of renal function may be warranted in these individuals. Additionally, it is important to evaluate the patient’s nutritional status and dietary intake of folate to ensure comprehensive management of their condition. Pregnant and lactating women should use folic acid under medical supervision to determine appropriate dosing.

Clinical Studies

Clinical studies have demonstrated the efficacy of folic acid in treating megaloblastic anemia and preventing neural tube defects in pregnancy. A randomized controlled trial published in the Journal of Nutrition indicated that folate supplementation significantly improved hematological parameters in patients with folate deficiency anemia. Another study published in the American Journal of Clinical Nutrition highlighted the role of folate in reducing the risk of cardiovascular events by lowering homocysteine levels. These findings support the therapeutic use of VICTOFOL INJ 10ML in clinical practice.

Conclusion

VICTOFOL INJ 10ML is a valuable therapeutic option for patients with folate deficiency and related conditions. Its mechanism of action, pharmacological properties, and clinical efficacy make it an essential component of treatment protocols for megaloblastic anemia and other folate-related disorders. However, careful consideration of contraindications, potential side effects, and drug interactions is crucial for ensuring patient safety and optimizing treatment outcomes. Healthcare providers should remain vigilant in monitoring patients receiving VICTOFOL to achieve the best possible results.